financetom
Business
financetom
/
Business
/
IRDAI growth targets for general insurance companies
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
IRDAI growth targets for general insurance companies
Jul 21, 2022 12:04 PM

The Insurance Regulatory and Development Authority (IRDAI) has not just set growth targets for life insurance companies, but it has made sure the general insurance industry is not out of this net as well.

Share Market Live

NSE

If one thought that the premium growth targets for life insurance companies were steep, then with the general insurance companies these targets only get more aggressive.

IRDAI intends to take the general insurance penetration in India to 2.5 percent by the 2026-27 fiscal from the present 1 percent. The insurance penetration is the ratio of premium top GDP and here the insurance regulator wants to take the premium collected by general insurance industry from Rs 2.2 lakh crore all the way up to Rs 11.7 lakh crore.

Just like for life insurance companies, these growth targets for general insurers have been set based on their past performance, their distribution network and their current premium base.

Targets for some of the large and listed general insurance companies

For ICICI Lombard, the IRDAI has proposed a target of 40 percent premium growth. It is expected to grow year-on-year till FY27. For New India Assurance, the IRDAI has proposed a premium growth target of 25 percent. For Bajaj Allianz General Insurance, the proposed target stands at 38 percent and for SBI General and Star Health Insurance it is 35 percent and 45 percent, respectively.

How does the historical growth rate compare to the IRDAI target

No doubt, the targets for general insurance companies are tall, but here is how the historical growth rate compare to the IRDAI target for these companies for example — ICICI Lombard and New India Assurance.

For ICICI Lombard, the strongest growth of 30 percent came in FY22, which was also because of a strong base effect. The target for ICICI Lombard is still away at 40 percent.

For New India Assurance, the best growth came in FY20 and FY22 of around 12 percent. Looking at the IRDAI target, the New India Assurance would have to more than double its premium to achieve these targets.

Also Read: Insurace regulator sets growth targets for life as well as general insurance companies

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
SoftBank in talks to lead OpenAI funding round at $300 billion valuation, sources say
SoftBank in talks to lead OpenAI funding round at $300 billion valuation, sources say
Jan 30, 2025
Jan 30 (Reuters) - SoftBank is in talks to lead a funding round of up to $40 billion in OpenAI at a post-money valuation of $300 billion, sources told Reuters, in what could be the largest ever single funding round for a private company. SoftBank has offered a term sheet that would value OpenAI at a pre-money valuation, meaning the...
Soccer-'Anything is possible' - Amorim says Man United must target trophy
Soccer-'Anything is possible' - Amorim says Man United must target trophy
Jan 30, 2025
BUCHAREST, Jan 30 (Reuters) - Ruben Amorim insisted that despite his difficult start as Manchester United ( MANU ) manager, his side must target winning the Europa League after booking their last-16 spot with a 2-0 victory at Steaua Bucharest on Thursday. Amorim became the first United manager to lose five of his first 10 games in all competitions since...
Koru Partners With Pharmaceutical Firm for Late-Stage Trial of Prospective Kidney Treatment
Koru Partners With Pharmaceutical Firm for Late-Stage Trial of Prospective Kidney Treatment
Jan 30, 2025
06:03 PM EST, 01/30/2025 (MT Newswires) -- Koru Medical Systems ( KRMD ) late Thursday disclosed plans to begin a late-stage trial for a new indication of an existing commercialized drug therapy through a collaboration with an unnamed pharmaceutical manufacturer to evaluate the safety, efficacy and performance of the drug for treating patients with a rare renal disorder following kidney...
Methode Electronics Names Karen Keegans as Chief Human Resources Officer
Methode Electronics Names Karen Keegans as Chief Human Resources Officer
Jan 30, 2025
06:00 PM EST, 01/30/2025 (MT Newswires) -- Methode Electronics ( MEI ) appointed Karen Keegans as chief human resources officer, effective Feb. 3, succeeding Andrea Barry. Keegans most recently was chief human resources officer at Suncor Energy ( SU ), Methode Electronics ( MEI ) said Thursday in a statement. Barry will be a special adviser to general counsel through...
Copyright 2023-2026 - www.financetom.com All Rights Reserved